共 277 条
[1]
Shepard CW(2005)Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 558-567
[2]
Finelli L(2002)Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future Oncology 62 8-17
[3]
Alter MJ(1993)Significance of serum hepatitis C virus RNA in chronic hepatitis C Lancet 22 1351-1354
[4]
Yoshizawa H(2000)Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 1666-1672
[5]
Lau JY(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 958-965
[6]
Davis GL(2010)Geneteic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 1338-1345
[7]
Kniffen J(2006)Review article: predicting response in hepatitis C virus therapy Aliment Pharmacol Ther 23 1043-1054
[8]
Qian KP(2009)Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C J Gastroenterol 44 1009-1015
[9]
Urdea MS(2004)Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: Randomized study of the effect of treatment duration and ribavirin dose Ann Intern Med 140 346-355
[10]
Chan CS(2009)A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan Hepatol Int 3 468-479